Evidence map›Paper›PMID 33798201›Full record

ArticlePloS one2021

The impact of routine HIV drug resistance testing in Ontario: A controlled interrupted time series study.

Lawrence Mbuagbaw, Carmen H Logie, Lehana Thabane, Fiona Smaill, Marek Smieja, Ann N Burchell, Beth Rachlis, Jean-Eric Tarride, Abigail Kroch, Tony Mazzulli and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Lawrence MbuagbawDepartment of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada.ORCID 0000-0001-5855-5461
Carmen H LogieWomen's College Research, Toronto, ON, Canada.
Lehana ThabaneDepartments of Paediatrics and Anaesthesia, McMaster University, Hamilton, ON, Canada.
Fiona SmaillDepartment of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada.
Marek SmiejaDepartment of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada.
Ann N BurchellDepartment of Family and Community Medicine, Faculty of Medicine, University of Toronto, Toronto, ON, Canada.
Beth RachlisDivision of Clinical Public Health, Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada.
Jean-Eric TarrideDepartment of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada.
Abigail KrochOntario HIV Treatment Network, Toronto, Ontario, Canada.
Tony MazzulliDepartment of Laboratory Medicine and Pathobiology, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.
Elizabeth AlvarezDepartment of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada.
Daeria O LawsonDepartment of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada.
Francis NguyenICES McMaster, McMaster University, Hamilton, Ontario, Canada.
Richard PerezICES McMaster, McMaster University, Hamilton, Ontario, Canada.
Hsien SeowDepartment of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada.ORCID 0000-0001-6701-1714

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundKnowledge of HIV drug resistance informs the choice of regimens and ensures that the most efficacious options are selected. In January 2014, a policy change to routine resistance testing was implemented in Ontario, Canada. The objective of this study was to investigate the policy change impact of routine resistance testing in people with HIV in Ontario, Canada since January 2014.

methodsWe used data on people with HIV living in Ontario from administrative databases of the Institute for Clinical Evaluative Sciences (ICES) and Public Health Ontario (PHO), and ran ordinary least squares (OLS) models of interrupted time series to measure the levels and trends of 2-year mortality, 2-year hospitalizations and 2-year emergency department visits before (2005-2013) and after the policy change (2014-2017). Outcomes were collected in biannual periods, generating 18 periods before the intervention and 8 periods after. We included a control series of people who did not receive a resistance test within 3 months of HIV diagnosis.

resultsData included 12,996 people with HIV, of which 8881 (68.3%) were diagnosed between 2005 and 2013, and 4115 (31.7%) were diagnosed between 2014 and 2017. Policy change to routine resistance testing within 3 months of HIV diagnosis led to a decreasing trend in 2-year mortality of 0.8% every six months compared to the control group. No significant differences in hospitalizations or emergency department visits were noted.

interpretationThe policy of routine resistance testing within three months of diagnosis is beneficial at the population level.

Indexed as

Drug Resistance, ViralAdultAnti-HIV AgentsFemaleHIVHIV InfectionsHospitalizationHumansInterrupted Time Series AnalysisMaleMiddle AgedOntarioYoung AdultAnti-HIV Agents

Identifiers

PMID33798201
PMCPMC8018617

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.